Nautilus Biotechnology, Inc. — Form 10-Q
Filed October 27, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Sujal Patel (CEO) and Anna Mowry (CFO) signed standard Sarbanes-Oxley 302 and 906 certifications for Nautilus Biotechnology's Q3 2026 10-Q filed October 27, 2026. Both officers certified that financial statements fairly present the company's condition and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, significant deficiencies, or fraud disclosures were identified in the certifications.
Why this rating
Routine quarterly certification required by SOX. Standard boilerplate with no red flags; absence of control weaknesses is marginally positive for a microcap.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.